Orthofix Medical Inc expected to post a loss of 8 cents a share - Earnings Preview

Orthofix Medical

01/03/2024 22:17

* Orthofix Medical Inc  OFIX.OQ   OFIX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 5
for the period ending December 31 2023
    * The Lewisville Texas-based  company is expected to report
a
59.8% increase in revenue to $195.314 million from $122.23
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Orthofix Medical Inc is
for a
loss of 8 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Orthofix
Medical
Inc is $14.00​, above​ its last closing price of $13.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.21       -0.21      0.07      Beat    133.5
 Jun. 30 2023  -0.45       -0.47      0.02      Beat    104.2
 Mar. 31 2023  -0.52       -0.51      -0.10     Beat    80.4​
 Dec. 31 2022  0.34        0.10       0.19      Beat    83.9
 ​​Sep.        0.13        0.12       0.13      Beat    11.4
 30 2022                                                
 Jun. 30 2022  0.10        0.10       0.08      Missed  -20​
 Mar. 31 2022  0.10        0.09       -0.10     Missed  -215.4
 Dec. 31 2021  0.13        0.13       0.27      Beat    107.7
 This summary was machine generated March 1 at 22:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)